Four new policies under development may address a variety of lingering regulatory hurdles for foreign drug and device companies in China.
China Market Intelligence
China’s Unreliable Entity List: What’s Next? May 27th, 2020
Phase One Implementation Update: Progress on Structural Reforms, While Purchases Fall Short May 27th, 2020
June 14th, 2017
May 3rd, 2017
As China aims to expand nationwide health insurance, improve patient access to care, strengthen primary care, and deepen investment in rural regions, US companies want in on the